Vimarsana
Biggest News Aggregation in the World

Acta Derm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acta Derm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acta Derm Today - Breaking & Trending Today

Study: Visible AD Impacts Romantic Relationships, Occupation, Sexual Health of French Female Patients - Vimarsana News

Study: Visible AD Impacts Romantic Relationships, Occupation, Sexual Health of French Female Patients

Atopic dermatitis (AD) in visible areas significantly impacts the romantic relationships, occupations, and sexual health of French female adult patients, according to a new study.

Source: ajmc.com
UV Phototherapy: Utilization in Patients with Dermatologic Disease, Co-Medications - Vimarsana News

UV Phototherapy: Utilization in Patients with Dermatologic Disease, Co-Medications

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 - Vimarsana News

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 •    Hidradenitis suppurativa (HS) is a painful, chronic and progressive inflammatory skin disease with over 50% of people reporting a mental health impact1,2 &bu...

Phimosis | Tight Foreskin - Causes - Symptoms - Vimarsana News

Phimosis | Tight Foreskin - Causes - Symptoms

Phimosis or tight foreskin is the inability to fully retract the foreskin over the glans penis due to a narrow opening.

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx® - Vimarsana News

Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®